Document Detail

HER-2/NEU overexpression in vulvar Paget disease: the Yale experience.
MedLine Citation:
PMID:  20418225     Owner:  NLM     Status:  MEDLINE    
AIMS: To determine the level of HER-2/neu overexpression in vulvar Paget disease (PD) in order to assess the possibility of using HER-2/neu as a target for the treatment of Paget disease.
METHODS: A medical record search identified 39 patients with a histologically confirmed diagnosis of vulvar PD between 1986 and 2009. A tissue microarray containing all 39 tumour samples was created, and corresponding sections were stained immunohistochemically with an anti-HER-2/neu-antibody (HercepTest). Staining results were reported on a scale from 0 to 3+. 2+ and 3+ were considered as HER-2/neu overexpression. The HER-2/neu expression was correlated with clinical, pathological and outcome data.
RESULTS: Negative staining for HER-2/neu was noticed in four patients (12%), 1+ in 10 patients (30%), 2+ in 11 patients (33%) and 3+ in eight patients (25%), resulting in 19 patients with HER-2/neu overexpression (2+ and 3+, 58%) and 14 patients without HER-2/neu overexpression (0 and 1+, 42%). The proportion of HER-2/neu overexpression was higher in the patients with invasive than with non-invasive PD (71%, n=5/7 invasive PD vs 54%, n=14/26 non-invasive PD). There was no significant correlation between HER-2/neu staining results and clinical, pathological or outcome data.
CONCLUSIONS: Surgical treatment of vulvar Paget disease is associated with a high recurrence rate and extensive reconstructive procedures. In this study, over 50% of the patients with vulvar Paget disease overexpress HER-2/neu. Anti-HER-2/neu-antibodies like trastuzumab may therefore be an interesting treatment option for HER-2/neu-positive vulvar Paget disease. Clinical trials are needed to evaluate the efficacy of trastuzumab in this disease.
Christine E Richter; Pei Hui; Natalia Buza; Dan-Arin Silasi; Masoud Azodi; Alessandro D Santin; Peter E Schwartz; Thomas J Rutherford
Related Documents :
21804855 - Infliximab induces increase in triglyceride levels in psoriatic arthritis patients.
745015 - Overview of present day treatment of parkinson's disease.
1591735 - Chronic administration of l-dopa affects the movement-related cortical potentials of pa...
2006005 - The occurrence of motor fluctuations in parkinsonian patients treated long term with le...
23230555 - Specimen index may be a predictive factor for recurrence after primary closure of pilon...
20625045 - Clinical features of tuberculous serpiginouslike choroiditis in contrast to classic ser...
Publication Detail:
Type:  Journal Article     Date:  2010-04-23
Journal Detail:
Title:  Journal of clinical pathology     Volume:  63     ISSN:  1472-4146     ISO Abbreviation:  J. Clin. Pathol.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-05-25     Completed Date:  2011-01-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376601     Medline TA:  J Clin Pathol     Country:  England    
Other Details:
Languages:  eng     Pagination:  544-7     Citation Subset:  AIM; IM    
Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Middle Aged
Neoplasm Invasiveness
Paget Disease, Extramammary / metabolism*,  pathology,  therapy
Receptor, erbB-2 / metabolism*
Treatment Outcome
Tumor Markers, Biological / metabolism*
Vulvar Neoplasms / metabolism*,  pathology,  therapy
Reg. No./Substance:
0/Tumor Markers, Biological; EC protein, human; EC, erbB-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Addressing modifiable risk factors for coronary heart disease in primary care: an evidence-base lost...
Next Document:  Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-cul...